leadf
logo-loader
viewOpen Orphan PLC
(
AIM:ORPHFRA:CRO
)

Open Orphan unit Venn Life Sciences lands two new clients

Chairman Cathal Friel said: "As we come towards the end of 2020, it's wonderful to see all the elements of the Open Orphan business are delivering substantial revenues and both new contract wins and renewal of existing long-term customer contracts"

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) said its Venn Life Sciences drug development subsidiary has been awarded two new contracts that start immediately.

The first will see Venn’s Paris team manage the randomisation and supply management for a coronavirus (COVID-19) trial to be conducted by an unnamed European pharmaceutical company.

The team in Breda, in the Netherlands, meanwhile, will deploy its expertise to deliver process improvements in clinical development for the second new client.

In a statement, Open Orphan chairman Cathal Friel said: "As we come towards the end of 2020, it's wonderful to see all the elements of the Open Orphan business are delivering substantial revenues and both new contract wins and renewal of existing long-term customer contracts."

He added that merger and integration of Open Orphan, Venn and hVIVO, the viral challenge study specialist, was “very much now complete” with the enlarged business now profitable.

“Both Venn and hVIVO are converting their substantial pipeline of work whilst providing a high-quality service to their customers,” explained Friel.

“The Paris team's contract is a further demonstration of our work in the fight against COVID-19 and the contract win by our Dutch Breda team shows how we continue to generate repeat business through our expertise.”

Quick facts: Open Orphan PLC

Follow
AIM:ORPH

Price: 22.75 GBX

Market Cap: £152.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan reveal 'very good first half, firmly profitable, cash in bank...

Open Orphan PLC (AIM:ORPH, FRA:CRO)'s (LON:ORPH) Cathal Friel talks to Proactive London about their year-on-year revenue growth and profitable first half following a 'year of turnaround and transition in 2020'.  As Friel explains, these results show a continued pattern of profitability from...

2 days, 10 hours ago

2 min read